CLAIM AMENDMENTS

1-24. (canceled)

25. (currently amended): A pharmaceutical composition for parenteral administration, comprising particulate delivery vehicles having associated therewith at least a first ~~antineoplastic~~ agent and a second ~~antineoplastic~~ agent, wherein said first and second agents are in a mole ratio which exhibits a non-antagonistic ~~cytotoxic or cytostatic~~ desired biological effect in an *in vitro* assay, over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8; and wherein said first and second agents are associated with the delivery vehicles to maintain **[[**a**]]** said non-antagonistic ratio in the blood **[[**on**]]** for at least one hour after administration.

wherein said agents are effective for treating cardiovascular diseases, inflammation or autoimmune diseases, and

wherein said delivery vehicles comprise

liposomes, and/or

lipid micelles, and/or

block copolymer micelles, and/or

polymer microparticles, and/or

polymer nanoparticles, and/or

polymer lipid hybrid systems, and/or

derivatized single chain polymers.

26. (previously presented): The composition of claim 25 wherein said delivery vehicles are 4 to 6,000 nm in diameter.

27. (previously presented): The composition of claim 25 wherein said delivery vehicles have a mean diameter of between 4.5 and 500 nm.

28. (previously presented): The composition of claim 27 wherein said vehicles have a mean diameter of less than 250 nm.

29. (previously presented): The composition of claim 25 wherein said delivery vehicles are from 4μm to 50μm in diameter.

30. (previously presented): The composition of claim 25 wherein said delivery vehicles comprise liposomes.

31. (previously presented): The composition of claim 25 wherein said first and second agents are co-encapsulated.

32-40. (canceled)

41. (currently amended): A method to prepare a composition of claim 25, which method comprises

~~a) determining in a relevant cell culture assay for cytotoxic or cytostatic activity a mole ratio of said first and~~

~~second agent which is non-antagonistic over at least 5% of the concentration range over which greater than 1% of cells are affected by said ratio of agents, and~~

~~b) encapsulating~~ stably associating with said particulate delivery vehicles a mole ratio of agents that has been determined to [[be]] exhibit a non-antagonistic desired biological effect in ~~step a)~~ an *in vitro* assay over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8;

wherein said stable association is such that said ratio is maintained in the blood for at least one hour after administration.

42-44. (canceled)

45. (currently amended): The method of claim 41, wherein said ~~determining~~ ratio has been determined in an assay that employs testing at least one ratio of said agents at a multiplicity of concentrations and applying an algorithm to calculate a synergistic, additive, or antagonistic effect for said ratio over a range of concentrations.

46. (previously presented): The method of claim 45 which employs testing a multiplicity of ratios, and wherein said algorithm is the Chou-Talalay median effect method.

47-50. (canceled)

51. (previously presented): A method to treat a disease condition in a subject which method comprises administering to the subject an effective amount of the composition of claim 25.

52. (previously presented): The method of claim 51 wherein the subject is a human.

53. (previously presented): The method of claim 51 wherein the subject is a non-human mammal or avian.